ASRT

$12.50

Post-MarketAs of Mar 17, 8:00 PM UTC

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$12.50
Potential Upside
5%
Whystock Fair Value$13.12
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis,...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$80.21M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.79
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-24.48%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.41

Recent News

GuruFocus.com
Mar 17, 2026

Assertio Holdings Inc (ASRT) Q4 2025 Earnings Call Highlights: Navigating Challenges with ...

Despite a challenging quarter, Assertio Holdings Inc (ASRT) focuses on strategic growth opportunities and improved margins to drive future success.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Mar 17, 2026

Assertio Holdings, Inc. Q4 2025 Earnings Call Summary

Moby summary of Assertio Holdings, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Mar 16, 2026

Assertio Q4 Earnings Call Highlights

Assertio (NASDAQ:ASRT) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline a sharper strategic focus on growing its oncology franchise around Rolvedon, while becoming more selective on business development following what leadership described as a less capital-eff

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 16, 2026

Assertio (ASRT) Q4 2025 Earnings Call Transcript

Good afternoon, and thank you all for joining us today to discuss Assertio Holdings, Inc.'s fourth quarter 2025 financial results and business update. Please note that during this call, management will make projections and other forward-looking statements regarding our future performance. Such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, including those noted in this afternoon's press release as well as Assertio Holdings, Inc.'s filings with the SEC.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 16, 2026

Assertio (ASRT) Reports Q4 Loss, Beats Revenue Estimates

Assertio (ASRT) delivered earnings and revenue surprises of +39.02% and +185.10%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.